Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia

Trial Profile

A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2018

At a glance

  • Drugs Aceclidine/tropicamide (Primary)
  • Indications Presbyopia
  • Focus Therapeutic Use
  • Sponsors Presbyopia Therapies
  • Most Recent Events

    • 28 Aug 2018 Status changed from recruiting to completed.
    • 30 Jul 2018 Primary endpoint of (Proportion of subjects with at least a 3 line (15 letter) improvement in the study eye) has been met, according to a Presbyopia Therapies media release.
    • 30 Jul 2018 Results presented in the Presbyopia Therapies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top